MedTrace Logo

Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH

NCT07804524 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-09-04

No results posted yet for this study

Summary

To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in patients with pulmonary arterial hypertension PAH, who live permanently \>2600m.

Conditions

  • Pulmonary Arterial Hypertension (PAH)
  • Pulmonary Vascular Disease
  • High Altitude
  • Echocardiography
  • Pulmonary Resistance
  • Hemodynamic Changes

Interventions

BEHAVIORAL

Descent from 2850m to sea level

Descent from 2850m to sea level with a stay for 7 days

Sponsors & Collaborators

  • Silvia Ulrich Somaini

    lead OTHER

Principal Investigators

  • Silvia Ulrich · University Hospital Zurich, Departement of Pulmonology

  • Rodrigo Hoyos · Hospital Carlos Andrade Marin of Quito, Ecuador

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-25
Primary Completion
2026-10-04
Completion
2026-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07804524 on ClinicalTrials.gov